PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30157131-1	2019	Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis that interacts with the serotonin (5-HT)1A receptor, may possess analgesic and anxiolytic effects.	Cannabidiol	31-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	121-148	
30157131-1	2019	Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis that interacts with the serotonin (5-HT)1A receptor, may possess analgesic and anxiolytic effects.	Cannabidiol	44-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	121-148	
30157131-7	2019	Repeated treatment with CBD (5 mg/kg/day, subcutaneously [s.c.], for 7 days) increased 5-HT firing through desensitization of 5-HT1A receptors.	Cannabidiol	24-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	126-132	
30157131-11	2019	Overall, repeated treatment with low-dose CBD induces analgesia predominantly through TRPV1 activation, reduces anxiety through 5-HT1A receptor activation, and rescues impaired 5-HT neurotransmission under neuropathic pain conditions.	Cannabidiol	42-45	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134